SUMMARY
As a plan of therapy for shock associated with acute myocardial infarction in a general hospital and assuming that septic and hemorrhagic shock has been eliminated as diagnostic possibilities we would suggest the following:
(1) Pain should be relieved using morphine or pentazocine, and atropine if bradycardia is present. Oxygen by mask should be administered to bring the arterial oxygen tension to about 100 mm Hg. The airway must be examined and, if air exchange is poor and the artelial oxygen very low or carbon dioxide high, respiratory assistance and occasionally intubation may be required.
(2) Blood pressure must be stabilized at an adequate level for perfusion of vital organs, or progression may be so rapid that death will occur before proper evaluation can be made and more rational therapy started. For this purpose we would start a norepinephrine infusion at a rate just sufficient to keep the systolic blood pressure near 100 mm Hg. If the shock syndrome is present but arterial pressure is normal or only slightly reduced, we would eliminate this step in therapy.
(3) Arrhythmias or heart block should be corrected by methods discussed elsewhere in this symposium.
(4) A venous catheter should be inserted so that the catheter tip is just within the thorax. If the central venous pressure (CVP) is below 10 cm H20 we would begin a regimen of plasma volume expansion giving 100 cc of 40dextran over a peliod of 10 min, waiting 10 min, and if the CVP has not risen 1 cm H20 repeat the process until shock is relieved, the CVP continues to increase or is above 15 cm H20, or 1000 cc of 40dextran has been given. If the patient accepts more than 1000 cc of fluid in this manner without elevating the CVP it is most likely that some other major process causing fluid loss is complicating the myocardial infarction. (5) If or when CVP is above 10 cm H20, and if the patient remains in shock and is hypotensive, we would add norepinephrine infusion at a rate just sufficient to bring the systolic pressure between 100 and 110 mm Hg. If this cannot be accomplished with small amounts of norepinephrine then intraarterial pressure must be measured since the discrepancy between the cuff pressure and actual pressure may be increasing with further pressor infusion.
(6) If the patient is normotensive and has a CVP above 10 cm H20 but manifests the shock syndrome, an isoproterenol infusion should be instituted, but to use this regimen one must be able to measure intraarterial pressure. If CVP falls, simultaneous plasma volume expansion may be necessary. If arterial pressure begins to fall, norepinephrine should be substituted. We would use dopamine first in this particular situation, but this agent is not as yet generally available. 35 They made the very important observation that when the arterial pressure was brought above 90 mm Hg there was a decrease in cardiac output and an increase in systemic vascular resistance. We have reported on the use of norepinephrine in 33 patients in shock with acute myocardial infarction and all except one had control mean arterial pressure below 75 mm Hg.' Cardiac output increased an average of 18%, arterial pressure increased 43%, and systemic vascular resistance increased 37%.
We have reviewed our experience with the use of norepinephrine in patients with various forms of medical shock (table 1) and have confirmed the observations of Weil and Shubin36 that increasing the arterial pressure above levels just adequate to perfuse the vital organs (brain, heart, and kidney) merely increases the work of the heart at the expense of a decrease in blood flow. patients showed clinical improvement during isoproterenol infusion. There was rapid clinical deterioration in four patients on switching from norepinephrine to isoproterenol, and this was reversed by reinstituting norepinephrine in one.
The most conclusive report negating the usefulness of isoproterenol in shock and hypotension due to coronary disease has been that of Mueller et al. 42 3 They demonstrated that isoproterenol increased myocardial lactate production in all patients given this agent while with norepinephrine infusion lactate production shifted to extraction or extraction increased. This metabolic deterioration during isoproterenol infusion in spite of an increase in coronary blood flow may represent the "coronary steal syndrome" described by Sharma et al. 17 The maximally dilated vessels surrounding an infarct and behind areas of fixed obstruction have blood flow which is pressuredependent. An agent such as isoproterenol which drops perfusion pressure and decreases coronary resistance in uninvolved areas would divert blood away from the ischemic areas while increasing the oxygen needs of the ischemic myocardium. Bing et al. have shown that in ischemic muscle isoproterenol enhances peak tension but that deterioration occurs more rapidly than in ischemic muscle not exposed to isoproterenol.44 This increased rate of deterioration could be slowed but not reversed by the addition of glucose. The authors proposed that isoproterenol causes rapid depletion of high energy stores. Thus isoproterenol not only diverts blood from the ischemic areas but enhances myocardial deterioration in the ischemic area.
Despite these arguments against its use, isoproterenol may be an effective agent in the presence of the shock syndrome when intraarterial pressure is normal. Under these circumstances, isoproterenol should be given in small amounts of 0.5-2.0 gg/min and discontinued if arterial pressure falls or if arrhythmias appear. In patients with severe mitral insufficiency and acute myocardial infarction any increase in systemic vascular resistance only enhances the regurgitant flow and, therefore, isoproterenol is the catecholamine to be used first.
Isoproterenol can also be used after atropine in the presence of bradycardia but in most instances this will be a temporary measure while placing a pacing catheter. Idioventricular rhythms should not be brought much above 60 beats/min with this drug because of the danger of inducing ventricular tachycardia or fibrillation.
Dopamine
Dopamine is a precursor of norepinephrine and activates both the beta-and alphaadrenergic receptors.45 In addition this drug has vasodilator effects on the renal and mesenteric vessels not mediated through adrenergic receptors.46 Dopamine, by increasing myocardial oxygen consumption, reduces coronary vascular resistance.4 A direct effect of dopamine on the coronary circulation has not as yet been demonstrated. Because its action on the adrenergic receptors is intermediate between norepinephrine and isoproterenol and due to its renal vasodilator properties, dopamine has been considered a useful agent in the treatment of various shock states.48 Dopamine has been shown to improve hemodynamic abnormalities caused by experimental myocardial infarction as it tends to reverse the depression of myocardial function that follows coronary artery ligation.49 MacCannell et al. reported improvement in urine flow as well as arterial pressure and cardiac output during dopamine infusion in patients with shock of several etiologies.50 Talley et al. reported seven patients who had a better hemodynamic response to dopamine than to isoproterenol. 51 We have reported on the effects of dopamine on 62 patients with shock.52 In 13 patients, five of whom had acute myocardial infarction, the shock was primarily cardiogenie. In patients with cardiogenic shock dopamine increases cardiac output and LVEDP and can increase mean arterial pressure if it is reduced. Systemic vascular resistance tends to fall as cardiac output increases in those who are initially vasoconstricted. When compared to norepinephrine and isoproterenol, dopamine increases cardiac output more than norepinephrine and less than isoproterenol and increases arterial pressure more that isoproterenol and less than norepinephrine. Urine flow appears to improve as often with norepinephrine as with dopamine. Comparison of the latter two agents by therapeutic trial is often necessary if improved urine flow is the object of therapy.
Dopamine can be infused at rates of 0.1-1.6 mg/min, and careful ECG monitoring is necessary because ventricular arrhythmias may be precipitated.
Digitalis
Digitalis has been used in treatment of shock with myocardial infarction but few studies of the hemodynamic effects have been published. Gorlin measured cardiac output in two patients before and after rapid digitalization and found increases in both patients. 53 In an experimental model of cardiogenic shock Cronin and Zsoter showed that digitalis causes an increase in blood pressure, a slight increase in cardiac output, and a very significant increase in stroke volume with a fall in LVEDP. 54 The increase in blood pressure preceded the increase in cardiac output and they suggested that the direct vasoconstrictor effects of digitalis preceded the inotropic action.
We have reported the effects of acute digitalization in a group of patients in shock with myocardial infarction and the averages of the changes in cardiac output, arterial pressure, CVP, and systemic vascular resistance tended to show no effect of the digitalis on any of these parameters.' Some patients improved but others deteriorated or continued to deteriorate following administration of digitalis. Morrison and Killip have stressed the Circulation, Volume XLV, increased ventricular irritability induced by digitalis in acute myocardial infarction,55 and therefore it should be used judiciously and only after elevating the arterial pressure and by ensuring an adequate filling pressure by fluid infusion, if necessary. It should be given in amounts calculated to be one half to two thirds of the accepted "digitalizing" doses. The best effects will be in the patients in overt failure, but almost all patients with acute myocardial infarction given digitalis will decrease LVEDP and increase LV stroke work and rate of pressure development.
The question remains as to whether this effect is of benefit to the heart. The increase in stroke work and the increase in rate of pressure development would be at the expense of an increase in myocardial oxygen consumption.56 However, the decrease in LVEDP, if it represents a decrease in diastolic volume and not just a change in myocardial compliance, should decrease myocardial oxygen needs. The law of LaPlace indicates that the pressure in the ventricle varies directly with the tension in the wall and inversely with the radius of the cavity. Therefore, if left ventricular pressure develops from a smaller ventricular radius, myocardial tension, a major determinant of myocardial oxygen consumption, could decrease even as pressure rises. It is probable that the dilated heart benefits from administration of digitalis while the normal-sized heart does not. The answer to whether the effects in acute myocardial infarction are beneficial awaits studies of changes in ventricular volume or measurements of myocardial oxygen consumption. There is some indication from clinical observations that changes in ventricular volume may determine the efficacy of digitalis in ischemic heart disease, since patients with angina and small hearts not infrequently accelerate their angina with digitalization while patients with big hearts may be relieved of angina when given digitalis.57 Digitalis should not be given in the presence of heart block unless a pacemaker catheter is in place.
Glucagon
Glucagon has been noted to have an Circulation, Volume XLV, May 1972 inotropic effect in isolated muscle preparations and in the intact animal.58 In man it has been shown to be effective in increasing cardiac output, rate of pressure development, and heart rate.59 It was first used therapeutically as an inotropic agent by Linhart who reported improvement in a patient with depressed cardiac function after heart-valve replacement. 60 With administration of glueagon to this patient he noted that the blood pressure returned to normal, heart rate increased slightly, and further pharmacologic support was unnecessary. Parmley reported on the administration of this agent to 16 patients in the first postoperative day after prostheticvalve replacement and found an increase in mean arterial pressure, heart rate, and cardiac index.61 There was no change in systemic vascular resistance, although Glick had previously shown glueagon to be a mild vasodilator. 62 Vander Ark and Reynolds treated 16 patients with cardiogenic shock for 1-12 days with continuous glueagon infusions. 63 They noted improvement in 12 of the patients who experienced increased blood pressure, decreased heart rate, and increased urine flow. Murtagh et al. gave glueagon to eight patients with myocardial infaretion and noted an increase in pulmonary and systemic vascular resistances.64 Diamond et al. treated 10 patients with acute myocardial infarction, nine of whom had left ventricular failure.65 They noted an increase in heart rate, cardiac output, and arterial pressure. There was a consistent increase in pulmonary vascular resistance, and they attributed this to a direct effect of glucagon on the pulmonary vasculature. They also report the use of glucagon in treating two patients with severe myocardial infarction and shock, and credited survival in one of the patients to the use of glucagon. Studies The effects of isoproterenol (ISP), phentolamine, and glucagon in a patient with chronic congestive heart failure. Cardiac output (CO) increased more with isoproterenol thanz with glucagon hut urine flow (UF) was greater during glucagon infusion. Phentolamine infusion had little effect on either CO or UF. Changes in mean arterial pressure (MAP), heart rate (HR), and left ventricular end-diastolic pressu4re (LVEDP) are also show)n. although these same muscles responded positively to norepinephrine. Papillary muscle from patients with mitral stenosis and no left ventricular failure showed an inotropic response to both glucagon and norepinephrine. This discrepancy is probably due to uncoupling or disruption of the glucagon receptor mechanism in chronic congestive heart failure. 67 Glucagon acts by activating adenyl cyclase which converts adenosine triphosphate to cyclic AMP (adenosine 5'-monophosphate ) and this in turn activates the contractile mechanism.67 Catecholamines also activate adenyl cyclase but through a different receptor mechanism. Aminophylline will potentiate the effects of glucagon by blocking phosphodiesterase which deactivates cyclic AMP.69 Glucagon, therefore, has the advantage of acting through a nonadrenergic receptor mechanism and can be effective in the patient wvho has received beta-receptor blocking agents. It does not cause arrhythmias and can be used in the patient with digitalis excess. It has also been shown to reverse the prolongation of action potential produced by quinidine. 70 Administration is either by single injection of 4-5 mg intravenously or by constant intravenous infusion at the rate of 4-12 mg/hour. The single injection shows onset of action almost immediately, peak action at 10 min, and action is dissipated within 30 min. 71 Hyperglycemia is a constant finding, but is usually only to levels of 140 mg% and seldom exceeds 200 mg%. Hypoglycemia may occur, particularly on discontinuance after prolonged infusion. Hypokalemia occurs consistently and should be prevented by K-' supplementation during glucagon infusion. Glucagon infusion should be augmented by simultaneous aminophylline infusion. Nausea and vomiting are uncomfortable side effects and the resultant vagal stimulation may decrease cardiac output. By limiting the infusion rate or keeping the single injection below 5 mg this side effect usually can be avoided.
Glucagon has a direct effect on the renal tubules leading to diuresis and natriuresis.72 In chronic intractible cardiac failure we have noted marked diuresis far in excess of the hemodynamic effect and suggest that the direct renal effects deserve further study ( fig.  4 ).
Chlorpromazine and Phentolamine
Chlorpromazine73 and phentolamine have been used as vasodilators in myocardial infarction. They can be used in conjunction with norepinephrine to decrease the vasoconstrictor activity of the latter agent and thus allow more inotropic activity. Both agents also cause a decrease in venous tone and should be Circulation, Volume XLV, accompanied by volume administration unless the vasodilator is being used in management of pulmonary edema. Chlorpromazine is given in amounts of 5-10 mg intravenously in a single injection and may be repeated only once at 20-30 min. Larger amounts of this agent will increase drowsiness and may enhance arrhythmias. Phentolamine is given as a constant intravenous infusion at a rate of 2-4 mg/hour. Phenoxybenzamine, although a very potent alpha-adrenergic blocking agent, is not available for general use and its action is so prolonged that we would not think it should be used in acute myocardial infarction.
